MedTrace Logo

Comparison of the Effectiveness of the Ultrasound Guided Injections in Patients With Shoulder Impingement Syndrome

NCT05015322 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-08-20

No results posted yet for this study

Summary

Shoulder pain, which is the third most common cause of musculoskeletal pain, has different etiologies. Muscle, bone structures and connective tissue pathologies can cause shoulder pain. Impingement syndrome (IS), which can cover many terms such as rotator cuff disorders, tendinitis and tears, is one of the most common pathologies of shoulder pain.

Conditions

  • Shoulder Impingement
  • Ultrasound Guided Injection

Interventions

DRUG

bupivacaine and methylprednisolone

suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone

DRUG

bupivacaine and methylprednisolone

5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area

DRUG

bupivacaine and methylprednisolone

5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint

Sponsors & Collaborators

  • Bursa Yuksek Ihtisas Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Burcu Metin Ökmen, Assoc. Prof · University of Health Sciences, Yuksek Ihtisas Training and Research Hospital

  • Korgün M Ökmen, Assoc. Prof · Bursa Yuksek Ihtisas Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2021-01-01
Completion
2021-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05015322 on ClinicalTrials.gov